GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Frazier Lifesciences Acquisition Corp (NAS:FLAC) » Definitions » Market Cap

Frazier Lifesciences Acquisition (Frazier Lifesciences Acquisition) Market Cap : $175.20 Mil (As of Jun. 15, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Frazier Lifesciences Acquisition Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Frazier Lifesciences Acquisition's share price for the quarter that ended in Sep. 2022 was $9.97. Frazier Lifesciences Acquisition's Shares Outstanding (EOP) for the quarter that ended in Sep. 2022 was 17.75 Mil. Therefore, Frazier Lifesciences Acquisition's market cap for the quarter that ended in Sep. 2022 was $176.98 Mil.

Frazier Lifesciences Acquisition's quarterly market cap increased from Mar. 2022 ($174.49 Mil) to Jun. 2022 ($175.20 Mil) and increased from Jun. 2022 ($175.20 Mil) to Sep. 2022 ($176.98 Mil).

Frazier Lifesciences Acquisition's annual market cap stayed the same from . 20 ($0.00 Mil) to Dec. 2020 ($0.00 Mil) but then increased from Dec. 2020 ($0.00 Mil) to Dec. 2021 ($173.07 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Frazier Lifesciences Acquisition's Enterprise Value for Today is $174.83 Mil.

Frazier Lifesciences Acquisition Market Cap Historical Data

The historical data trend for Frazier Lifesciences Acquisition's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Frazier Lifesciences Acquisition Market Cap Chart

Frazier Lifesciences Acquisition Annual Data
Trend Dec20 Dec21
Market Cap
- 173.07

Frazier Lifesciences Acquisition Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Market Cap Get a 7-Day Free Trial Premium Member Only 174.31 173.07 174.49 175.20 176.98

Competitive Comparison of Frazier Lifesciences Acquisition's Market Cap

For the Shell Companies subindustry, Frazier Lifesciences Acquisition's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Frazier Lifesciences Acquisition's Market Cap Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Frazier Lifesciences Acquisition's Market Cap distribution charts can be found below:

* The bar in red indicates where Frazier Lifesciences Acquisition's Market Cap falls into.


Frazier Lifesciences Acquisition Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Frazier Lifesciences Acquisition's Market Cap for the fiscal year that ended in Dec. 2021 is calculated as

Market Cap (A: Dec. 2021 )=Share Price (A: Dec. 2021 )*Shares Outstanding (EOP) (A: Dec. 2021 )
=$9.75*17.751
=$173.07

Frazier Lifesciences Acquisition's Market Cap for the quarter that ended in Sep. 2022 is calculated as

Market Cap (Q: Sep. 2022 )=Share Price (Q: Sep. 2022 )*Shares Outstanding (EOP) (Q: Sep. 2022 )
=$9.97*17.751
=$176.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frazier Lifesciences Acquisition  (NAS:FLAC) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.

Frazier Lifesciences Acquisition Market Cap Related Terms

Thank you for viewing the detailed overview of Frazier Lifesciences Acquisition's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.

Frazier Lifesciences Acquisition (Frazier Lifesciences Acquisition) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Frazier Lifesciences Acquisition Corp (NAS:FLAC) » Definitions » Market Cap
Comparable Companies
OMEG LJAQ GSQB PRBM MURF ITAQ APCA JATT SGII MEPW GSHN PSTH XAMS:EPIC ASZ CCYC CVII KAHC DWAC IPOF PBAJ
Traded in Other Exchanges
N/A
Address
601 Union Street, Two Union Square, Suite 3200, Seattle, WA, USA, 9810
Website
https://www.frazierlifesciencesacquisition.com
Frazier Lifesciences Acquisition Corp is a blank check company.
Executives
David Joseph Topper director, officer: Chief Financial Officer C/O GENERAL ATLANTIC SERVICE COMPANY, LP, 55 EAST 52ND STREET, 32ND FLOOR, NEW YORK NY 10055
Krishna R Polu director C/O RAPTOR PHARMACEUTICAL CORP, 7 HAMILTON LANDING, SUITE 100, NOVATO CA 94949
Robert Jr. Baltera director 6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121
Carol Giltner Gallagher director C/O ATARA BIOTHERAPEUTICS, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Michael Bigham director 890 WINTER STREET, WALTHAM MA 02451
Deerfield Management Company, L.p. (series C) 10 percent owner, other: Possible Member of 10% Group 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Deerfield Mgmt L.p. 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Partners, L.p. 10 percent owner, other: Possible Member of 10% Group 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
James E Flynn 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Viking Global Investors Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Ole Andreas Halvorsen 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Parent Gp Llc 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Rose Sharon Shabet 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Illiquid Investments Sub-master Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Gp Llc 10 percent owner 55 RAILROAD AVENUE, GREENWICH CT 06830